Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial.

By W. Stummer, U. Pichlmeier, Thomas Meinel, O. Wiestler, F. Zanella, H. Reulen. The Lancet Oncology, 2006

3,126 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

PHOTODYNAMIC THERAPY OF CANCER: AN UPDATE (2011, result): “Stummer et al reported the results of the ALA study group, a multicenter prospective randomized controlled trial in Germany.(269) This trial compared the effectiveness of ALA-based FGR with CA CANCER J CLIN 2011;61:250–281”
Oncologic Photodynamic Therapy: Basic Principles, Current Clinical Status and Future Directions (2017, background): “Stummer and colleagues reported a more complete resection of tumors that led to improved progression–free survival in patients with malignant glioma [255].”
A Brain Tumor Molecular Imaging Strategy Using A New Triple-Modality MRI-Photoacoustic-Raman Nanoparticle (2012, neutral): “Several intra-operative optical methods have been suggested, either based on intrinsic tissue optical properties 3,9 or exogenous contrast agents 10–12 .”
Epidemiologic and Molecular Prognostic Review of Glioblastoma (2014, background): “Tumor fluorescence derived from 5-aminolevulinic acid enables more complete resections of contrast-enhancing tumor, leading to improved progression-free survival in patients with malignant gliomas (45).”